Cabozantinib for Advanced or Metastatic Cervical Carcinoma After Platinum Treatment Failure

Inclusion Criteria: * Female 18 years of age or older * Histologically confirmed recurrent unresectable or metastatic cervix carcinoma with squamous cell, adenocarcinoma or adenosquamous histology - - Patient may have received at least one prior chemotherapy regimen of platinum-based chemotherapy for recurrence or metastatic disease. * Cisplatin given in combination with radiation for a localized disease does not count as a prior chemotherapy. * Prior treatment for advanced/metastatic disease with bevacizumab is allowed. * Prior treatments with immune checkpoint inhibitors are allowed. - ECOG performance status 0-2 - Measurable disease per RECIST 1.1 * The subject must have recovered to baseline or CTCAE v.5.0 (Common Terminology Criteria for Adverse Events, version 5.0) ≤ Grade 1 from clinical toxicities related to any prior treatments, i.e chemotherapy or pelvis radiation unless AE(s) are clinically non-significant (for example alopecia) * Adequate organ and marrow function, defined as follows, based upon laboratory tests performed within 7 days before inclusion: * Absolute neutrophil count (ANC) ≥ 1000/mm3 (≥ 1.0 GI/L) * Platelets ≥ 100,000/mm3 (≥ 100 GI/L) * Hemoglobin ≥ 10 g/dL (≥ 100 g/L) (red blood cell transfusion is allowed) * Total bilirubin ≤ 1.5 fold the upper limit of normal (for subjects with Gilbert's disease, ≤ 3 mg/dL or ≤ 51.3 μmol/L) o Serum albumin ≥ 3.0 g/dL (≥ 30 g/L) * Calculated creatinine clearance ≥ 30 mL/min by the CKD-EPI method. * Al…